Quantitative Study on HRCT Phenotype of COPD

Peking University

Status: Completed

Conditions: Chronic Obstructive Pulmonary Disease

Study type: Observational

Funder types: Other

Identifiers

NCT04953611

2013116

Details and patient eligibility

About

To explore the HRCT phenotype of the combined COPD assessment staging system

Full description

HRCT can be rapidly and safely deployed has enabled COPD research to move beyond FEV1 by facilitating and amplifying clinical phenotyping measurements, providing quantitative information, and detecting significant responses to therapy even in the absence of significant FEV1 improvements.

We explore the HRCT phenotype of the combined COPD assessment staging system,and found that:

1. Airway remodeling occurs in COPD patients. CT shows varying degrees of bronchial wall thickness, area increasing and emphysema as the new GOLD classification Group A-D arising.
2. The GOLD Combined assessment staging system helps doctors choose an individualized treatment for the COPD patients

Enrollment: 150 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Age between 40 and 80 (including 40 and 80)
2. It meets the diagnostic criteria for COPD
3. No language communication barriers, or the family members who know the condition can complete the questionnaire on behalf of the patient, and the data are reliable;
4. Voluntarily agree to participate in this study

Exclusion criteria

1. Older than 80 or younger than 40
2. Pregnant women
3. Complicating with other lung diseases, such as asthma, pneumonia, bronchiectasis, lung abscess, interstitial lung disease, confirmed and suspected lung cancer of lung shadow, active pulmonary tuberculosis, etc
4. Previous lung surgery
5. Cognitive dysfunction
6. Unable to cooperate with lung function test.

Trial design

150 participants in 5 patient groups

Group A in GOLD

Description:

CAT\<10、mMRC 0-1、FEV1%≥50%、the frequency of acute exacerbations in the past year\<2；

Group B in GOLD

Description:

CAT≥10、mMRC≥2、FEV1%≥50%、the frequency of acute exacerbations in the past year\<2

Group C in GOLD

Description:

CAT\<10、mMRC 0-1、 FEV1%\<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1

Group D in GOLD

Description:

CAT≥10、mMRC≥2、FEV1%\<50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1

Control Group

Description:

not COPD